Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development
This collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.
- This collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.
- “This partnership is unique in that it provides country-of-origin rights to Canada for all therapies developed under the agreement.
- “UHN is world-class, and Providence has demonstrated its mRNA platform is on par with other major mRNA companies.
- This sets up Canada to be a leader in exporting life-saving therapies throughout the world while taking care of Canadians.”
Brad Wouters, Executive Vice President, Science and Research at the University Health Network added, “Our partnership with Providence demonstrates the strength of discovery research at the University Health Network and our potential to fuel innovative therapeutic options for patients.